RankingsPricing
  1. US-listed companies
  2. LIGAND PHARMACEUTICALS INC
  3. Raw

LIGAND PHARMACEUTICALS INC【LGND】

Market cap
$4B
P/E ratio
SummaryFinancials
Back to summarized table
Dec 31,
2011		Dec 31,
2012		Dec 31,
2013		Dec 31,
2014		Dec 31,
2015		Dec 31,
2016		Dec 31,
2017		Dec 31,
2018		Dec 31,
2019		Dec 31,
2020		Dec 31,
2021		Dec 31,
2022		Dec 31,
2023		Dec 31,
2024
Net income (loss)10-11112257-213143629-357-3352-4
Gain on sale of Pelican---------17--2-
Change in estimated fair value of contingent liabilities-1-2-4-5-5-3-3-30-13710-1
Depreciation, Depletion and Amortization33333111215182651523735
Gain from short-term investments----------17-4294668
Amortization/accretion of premium (discount) on investments, net------00510-1-0-011
Amortization of debt discount and issuance fees----10111244302317100
Loss (gain) on derivative instruments------------0-20
Gain on debt extinguishment-----------74--
Non-cash income from financial royalty assets-------------5
CECL adjustment to financial royalty assets--------------4
Impairment loss of financial royalty assets-------------31
Lease amortization expense-----------622
Share-based compensation3461112192521253139602641
Losses from equity method investment in Primrose Bio-----5-23-2423----2-13
Fair value adjustment to Primrose Bio securities investments--------------26
Deferred income taxes, net131-0-0220-11-45-30-75199-21-1216
Other----0----132018
Accounts receivable, net4-2-210-69830-252629-5536
Inventory-1-1-1-400132180-1211-10
Other economic rights------------5-
Accounts payable and accrued liabilities-12-5-3-3-4-2-2-5-7-13-3-514
Income taxes receivable and payable--------11-94-22-2
Deferred revenue--------1-29-18-60-1
Other assets and liabilities------------610-1
Net cash provided by operating activities-102121426394194-2955791385097
Acquisition of financial royalty assets-------------18
Proceeds from financial royalty assets-------------7
Purchases of property and equipment010002213491842
Purchases of short-term investments10---1661642541,4342,35742318151127226
Proceeds from sale of short-term investments1910-2162587132536395154210149229
Proceeds from maturity of short-term investments----571191108931,49564467254533
Cash paid for equity method investment------------151
Cash paid for Palvella notes receivable-------------3
Cash paid for Novan acquisition, net of restricted cash received--4149327612405--10-
Cash paid for the Agenus transaction-------------75
Cash paid for Apeiron acquisition, net of cash received-------------92
Cash paid for InvIOs investment-------------4
Proceeds from Derivative Instrument, Investing Activities-------------7
Other000-0----5-211--
Net cash used in (provided by) investing activities-251-5-2-113-143-84-42346723231164-12-144
Proceeds from Issuance of Common Stock05-----------37
Net cash transferred to OmniAb at OmniAb Separation-----------2--
Repayment at maturity/repurchase of 2023 Notes-10209---2182722215626177-
Payments under finance lease obligations---------109000
Cash paid for transaction costs related to OmniAb Transactions-----------7--
Cash paid for debt issuance costs---6---17----10
Proceeds from bond hedge settlement-------44012-190--
Proceeds from Stock Options Exercised-13596520333432266
Taxes paid related to net share settlement of equity awards-----1104416855
Payments to CVR Holders-------03212--
Net cash provided by (used) in financing activities304-1613082-8329-485-311-138-276-6097
Effect of exchange rate changes on cash and cash equivalents--------00-----1
Net increase (decrease) in cash and cash equivalents-------------49
Interest paid-------2643100
Taxes paid0-0000001042412919
Net cash paid for acquisitions--4149327612405--10-
Accrued Primrose transaction costs------------1-
Addition of right-of-use assets and lease liabilities-------------2
Accrued royalty from financial royalty assets------------0-
Accrued purchases of financial royalty assets------------0-
Accrued debt issuance costs------------00
Accrued fixed asset purchases--------0022-0
Unrealized Gain (Loss) on Investments--343-1000-0-0-000